Denosumab - Bone metastases from solid tumours
You are here : Home > Formulary Search > Denosumab - Bone metastases from solid tumours
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Denosumab
Indication :
Bone metastases from solid tumours
Group Name :
Keywords :
Brand Names Include :
XGEVA
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1
Other Drugs
Below are listed other drugs that are used to treat Bone metastases from solid tumours.
- No records returned.
Committee Recommendations (1)
NICE guidance discussed at the PCN. Denosumab is not a payment by results excluded drugs and should be funded from within tariff by the oncology department within the acute trusts. See Surrey West Sussex & Hampshire cancer network protocol at the link below for more information St Luke's SACT Protocols and Policies | Royal Surrey NHS Foundation Trust